216 related articles for article (PubMed ID: 19634715)
1. Anti-iL-10 mAb protection against experimental visceral leishmaniasis via induction of Th1 cytokines and nitric oxide.
Bhattacharjee S; Gupta G; Bhattacharya P; Adhikari A; Majumdar SB; Majumdar S
Indian J Exp Biol; 2009 Jun; 47(6):489-97. PubMed ID: 19634715
[TBL] [Abstract][Full Text] [Related]
2. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
Dey R; Majumder N; Bhattacharyya Majumdar S; Bhattacharjee S; Banerjee S; Roy S; Majumdar S
Scand J Immunol; 2007 Dec; 66(6):671-83. PubMed ID: 18021365
[TBL] [Abstract][Full Text] [Related]
3. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
4. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
Bimal S; Sinha S; Singh SK; Narayan S; Kumar V; Verma N; Ranjan A; Sinha PK; Das VN; Pandey K; Kar SK; Das P
Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
[TBL] [Abstract][Full Text] [Related]
5. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
6. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
Bhowmick S; Ravindran R; Ali N
Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
[TBL] [Abstract][Full Text] [Related]
7. CXC chemokine-mediated protection against visceral leishmaniasis: involvement of the proinflammatory response.
Gupta G; Bhattacharjee S; Bhattacharyya S; Bhattacharya P; Adhikari A; Mukherjee A; Bhattacharyya Majumdar S; Majumdar S
J Infect Dis; 2009 Oct; 200(8):1300-10. PubMed ID: 19743920
[TBL] [Abstract][Full Text] [Related]
8. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
Kushawaha PK; Gupta R; Sundar S; Sahasrabuddhe AA; Dube A
J Immunol; 2011 Dec; 187(12):6417-27. PubMed ID: 22079980
[TBL] [Abstract][Full Text] [Related]
9. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.
Nagill R; Mahajan R; Sharma M; Kaur S
Parasitol Int; 2009 Dec; 58(4):359-66. PubMed ID: 19638322
[TBL] [Abstract][Full Text] [Related]
10. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
11. IL-12 enhances Th1-type responses in human Leishmania donovani infections.
Ghalib HW; Whittle JA; Kubin M; Hashim FA; el-Hassan AM; Grabstein KH; Trinchieri G; Reed SG
J Immunol; 1995 May; 154(9):4623-9. PubMed ID: 7722314
[TBL] [Abstract][Full Text] [Related]
12. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
[TBL] [Abstract][Full Text] [Related]
14. Chromone linked nitrone derivative induces the expression of iNOS2 and Th1 cytokines but reduces the Th2 response in experimental visceral leishmaniasis.
Mallick S; Halder S; Dutta A; Dey S; Paul K; Maiti S; Bandyopadhyay C; Saha B; Pal C
Int Immunopharmacol; 2013 Apr; 15(4):772-9. PubMed ID: 23499679
[TBL] [Abstract][Full Text] [Related]
15. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.
Murray HW; Moreira AL; Lu CM; DeVecchio JL; Matsuhashi M; Ma X; Heinzel FP
J Infect Dis; 2003 Aug; 188(3):458-64. PubMed ID: 12870129
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.
Tewary P; Saxena S; Madhubala R
Vaccine; 2006 Mar; 24(13):2409-16. PubMed ID: 16413950
[TBL] [Abstract][Full Text] [Related]
17. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.
Bhaumik S; Basu R; Sen S; Naskar K; Roy S
Vaccine; 2009 Feb; 27(9):1306-16. PubMed ID: 19162111
[TBL] [Abstract][Full Text] [Related]
18. Direct evidence for role of anti-saliva antibodies against salivary gland homogenate of P. argentipes in modulation of protective Th1-immune response against Leishmania donovani.
Pushpanjali ; Thakur AK; Purkait B; Jamal F; Singh MK; Ahmed G; Bimal S; Kumar V; Singh SK; Keshri S; Das P; Narayan S
Cytokine; 2016 Oct; 86():79-85. PubMed ID: 27484246
[TBL] [Abstract][Full Text] [Related]
19. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
Narayan S; Bimal S; Singh SK; Gupta AK; Singh VP; Sinha PK; Das P
Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
[TBL] [Abstract][Full Text] [Related]
20. Immunization with Leishmania infantum released proteins confers partial protection against parasite infection with a predominant Th1 specific immune response.
Rosa R; Marques C; Rodrigues OR; Santos-Gomes GM
Vaccine; 2007 Jun; 25(23):4525-32. PubMed ID: 17478016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
